MOTS-c dosing schedule
> Updated:
Human schedule
MOTS-c is a mitochondrial-derived peptide administered subcutaneously (injection) in studies and protocols. The table below is a generalized reference to described regimens, not a clinical recommendation.
This is a concise reference to regimens described for adults; it is not an individual prescription.
MOTS-c dosing in research protocols is set individually for each experiment, so the schedule below is a reference point drawn from published data, not a standard for self-administration.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 2.5–5 mg, 3x weekly | Starting dose |
| Standard regimen | 5 mg, 2–3x weekly | Increase if needed |
| Upper range (4–8-week cycle) | 10 mg, 2–3x weekly | Maximum in this schedule |
Practical dosing and effect details
Research protocols set the MOTS-c dose around a specific experimental goal, and published literature gives a clear example of how administration frequency ties to an observed effect. In a study by Reynolds and colleagues (Nature Communications, 2021), MOTS-c administration improved physical performance in mice across three age groups: young (2 mo.), middle-aged (12 mo.), and old (22 mo.). In a separate part of the same study, old mice (23.5 mo.) received the peptide intermittently, three times a week; this raised endurance and health measures in the aged animals. These results come from mice only and do not prove an effect in humans.
The schedule on this page (2.5–5 mg starting dose, 5 mg standard, 10 mg upper range) reflects the same logic of frequent, short administration rather than one large dose: the peptide's half-life in blood is measured in minutes, so infrequent injections poorly sustain its level across a research window.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.